we have difficult times at the moment. very few stocks will appreciate the real achievements that they are making.
one key point is that James has confirmed multiple times that the company is well financed this year; hence no need to tap the market in this storm.
they will deliver throughout the year and with both ongoing trials expected to be successful.
they could try to keep it simple/cheap for the next sepsis trial. i would think (no expert on Australian regulation for trials) that it would be relatively easy getting a pivotal trial for sepsis in Australia approved and not as costly as doing it in the EU or US. would be a sensible defensive approach with less capital requirements, should the markets still be in turmoil.
on the other hand the ideal case would be, if they could find a bigger partner (non-dilutive financing agreement) for a trial in the EU and/or US.
fundamentals looking great, but we will need to weather the ups and downs of the near future
RCE Price at posting:
93.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)